Corvus Pharmaceuticals (CRVS) was upgraded by The Goldman Sachs Group, Inc. to "strong-buy".
Corvus Pharmaceuticals (CRVS) is now covered by The Goldman Sachs Group, Inc.. They set a "buy" rating on the stock.
Corvus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Assessing Corvus Pharmaceuticals (CRVS) Valuation After Rapid Multi-Year Share Price Gains [Yahoo! Finance]
Corvus Pharmaceuticals (CRVS) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $33.00 price target on the stock, up from $32.00.